Figure 2.

In vitro anti-tumour activity of SHR-a14A1403 in PDAC cells. (A) qRT-PCR analysis was used to detect relative MET expression in a normal pancreatic ductal cell line (HPNE) and five pancreatic cancer cell lines. (B) Western blot analysis was used to detect the expression of c-MET in a normal pancreatic ductal cell line (HPNE) and five pancreatic cancer cell lines. (C) IC₅₀ values were determined using CCK-8 assays by treating cells with different concentrations of SHR-A1403 for 72 h. Data are presented as means ± SD of three independent experiments. (D) Colony formation assay to detect the proliferation of Aspc-1 cells treated with different concentrations of SHR-A1403. (E) Expression of EMT-related proteins after SHR-A1403 treatment. (F) Transwell assay to detect the migration ability of Aspc-1 cells treated with different concentrations of SHR-A1403. Migrated cells were quantified using ImageJ. (G) Cell cycle analysis to detect cell cycle changes in Aspc-1 cells treated with different concentrations of SHR-A1403. GraphPad Prism7 was used for quantitative statistics. (H) Apoptosis assay in Aspc-1 cells treated with different concentrations of SHR-A1403. Graphpad Prism 7 was used for quantitative statistics. **P < 0.01, ***P < 0.001. PDAC, pancreatic ductal adenocarcinoma; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SD, standard deviation; EMT, epithelial-mesenchymal transition.